Optune - Revision history

Lazy at 08:24, 18 January 2025

2025-01-18T08:24:49Z

← Older revision		Revision as of 01:24, 18 January 2025
Line 15:		Line 15:
	\|notes=Optune's significance is underscored by its addition to standard care for glioblastoma, showing remarkable survival benefits. It exemplifies the potential for non-invasive therapies in treating aggressive cancers, suggesting a paradigm shift in oncological treatments.		\|notes=Optune's significance is underscored by its addition to standard care for glioblastoma, showing remarkable survival benefits. It exemplifies the potential for non-invasive therapies in treating aggressive cancers, suggesting a paradigm shift in oncological treatments.
	\|treatment_category=Innovative Cancer Therapies		\|treatment_category=Innovative Cancer Therapies
	}}		\|overview=Optune, including its latest version Optune Gio®, is an innovative, non-invasive cancer therapy approved for newly diagnosed glioblastoma, demonstrating significant survival benefits when combined with temozolomide, as evidenced by the landmark EF-14 trial. With ongoing trials exploring its use for other cancers, Optune represents a potential paradigm shift in oncological treatments, offering improved quality of life and reduced systemic toxicity for patients.}}

69.163.248.232: Updated category= to treatment_category= in TreatmentInfo template

2024-11-12T18:38:58Z

Updated category= to treatment_category= in TreatmentInfo template

← Older revision		Revision as of 11:38, 12 November 2024
Line 14:		Line 14:
	\|book_text=Optune, now including Optune Gio® as its latest version, has shown significant survival benefits for newly diagnosed glioblastoma patients, especially when used in combination with temozolomide. It has been a part of a landmark phase 3 trial (EF-14) that demonstrated a considerable extension in both overall survival and progression-free survival. An ongoing TRIDENT trial is further investigating its efficacy in conjunction with radiation therapy and temozolomide from the onset of treatment. Optune represents a shift towards non-invasive cancer treatment modalities with reduced systemic toxicity and improved quality of life for patients.		\|book_text=Optune, now including Optune Gio® as its latest version, has shown significant survival benefits for newly diagnosed glioblastoma patients, especially when used in combination with temozolomide. It has been a part of a landmark phase 3 trial (EF-14) that demonstrated a considerable extension in both overall survival and progression-free survival. An ongoing TRIDENT trial is further investigating its efficacy in conjunction with radiation therapy and temozolomide from the onset of treatment. Optune represents a shift towards non-invasive cancer treatment modalities with reduced systemic toxicity and improved quality of life for patients.
	\|notes=Optune's significance is underscored by its addition to standard care for glioblastoma, showing remarkable survival benefits. It exemplifies the potential for non-invasive therapies in treating aggressive cancers, suggesting a paradigm shift in oncological treatments.		\|notes=Optune's significance is underscored by its addition to standard care for glioblastoma, showing remarkable survival benefits. It exemplifies the potential for non-invasive therapies in treating aggressive cancers, suggesting a paradigm shift in oncological treatments.
	\|~~category~~=Innovative Cancer Therapies		\|treatment_category=Innovative Cancer Therapies
	}}		}}

Lazy at 14:10, 29 March 2024

2024-03-29T14:10:00Z

← Older revision		Revision as of 07:10, 29 March 2024
Line 5:		Line 5:
	\|clinical_trial_phase=Phase 3 (EF-14 Trial); Phase 3 TRIDENT trial ongoing		\|clinical_trial_phase=Phase 3 (EF-14 Trial); Phase 3 TRIDENT trial ongoing
	\|common_side_effects=Mild to moderate skin irritation beneath transducer arrays, thrombocytopenia, nausea, constipation, vomiting, fatigue, headache, convulsions, depression		\|common_side_effects=Mild to moderate skin irritation beneath transducer arrays, thrombocytopenia, nausea, constipation, vomiting, fatigue, headache, convulsions, depression
			\|OS_without=16 months (control group in EF-14 Trial)
	\|OS_with=20.9 months (Optune plus temozolomide, final EF-14 analysis)		\|OS_with=20.9 months (Optune plus temozolomide, final EF-14 analysis)
			\|PFS_without=4 months (control group in EF-14 Trial)
	\|PFS_with=7.1 months (Optune arm in EF-14 Trial); 6.7 months from diagnosis in updated analysis		\|PFS_with=7.1 months (Optune arm in EF-14 Trial); 6.7 months from diagnosis in updated analysis
	\|usefulness_rating=5		\|usefulness_rating=5

Lazy: Created page with "{{TreatmentInfo |drug_name=Optune (Optune Gio® for newer version) |FDA_approval=Approved for newly diagnosed glioblastoma in October 2015; ongoing trials for broader applications |used_for=Newly diagnosed glioblastoma, with trials for other cancers ongoing |clinical_trial_phase=Phase 3 (EF-14 Trial); Phase 3 TRIDENT trial ongoing |common_side_effects=Mild to moderate skin irritation beneath transducer arrays, thrombocytopenia, nausea, constipation, vomiting, fatigue, he..."

2024-03-29T14:05:49Z

Created page with "{{TreatmentInfo |drug_name=Optune (Optune Gio® for newer version) |FDA_approval=Approved for newly diagnosed glioblastoma in October 2015; ongoing trials for broader applications |used_for=Newly diagnosed glioblastoma, with trials for other cancers ongoing |clinical_trial_phase=Phase 3 (EF-14 Trial); Phase 3 TRIDENT trial ongoing |common_side_effects=Mild to moderate skin irritation beneath transducer arrays, thrombocytopenia, nausea, constipation, vomiting, fatigue, he..."

New page

{{TreatmentInfo
|drug_name=Optune (Optune Gio® for newer version)
|FDA_approval=Approved for newly diagnosed glioblastoma in October 2015; ongoing trials for broader applications
|used_for=Newly diagnosed glioblastoma, with trials for other cancers ongoing
|clinical_trial_phase=Phase 3 (EF-14 Trial); Phase 3 TRIDENT trial ongoing
|common_side_effects=Mild to moderate skin irritation beneath transducer arrays, thrombocytopenia, nausea, constipation, vomiting, fatigue, headache, convulsions, depression
|OS_with=20.9 months (Optune plus temozolomide, final EF-14 analysis)
|PFS_with=7.1 months (Optune arm in EF-14 Trial); 6.7 months from diagnosis in updated analysis
|usefulness_rating=5
|toxicity_level=2
|toxicity_explanation=Most common adverse reaction is skin irritation at the device contact points; no increase in systemic adverse events
|book_text=Optune, now including Optune Gio® as its latest version, has shown significant survival benefits for newly diagnosed glioblastoma patients, especially when used in combination with temozolomide. It has been a part of a landmark phase 3 trial (EF-14) that demonstrated a considerable extension in both overall survival and progression-free survival. An ongoing TRIDENT trial is further investigating its efficacy in conjunction with radiation therapy and temozolomide from the onset of treatment. Optune represents a shift towards non-invasive cancer treatment modalities with reduced systemic toxicity and improved quality of life for patients.
|notes=Optune's significance is underscored by its addition to standard care for glioblastoma, showing remarkable survival benefits. It exemplifies the potential for non-invasive therapies in treating aggressive cancers, suggesting a paradigm shift in oncological treatments.
|category=Innovative Cancer Therapies
}}